Two Sigma Advisers’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-58,900
Closed -$12.4K 2643
2023
Q2
$12.4K Buy
58,900
+600
+1% +$104 ﹤0.01% 2341
2023
Q1
$9.33K Sell
58,300
-73,600
-56% -$32.7K ﹤0.01% 2543
2022
Q4
$73.2K Sell
131,900
-192,700
-59% -$164K ﹤0.01% 2329
2022
Q3
$386K Sell
324,600
-156,500
-33% -$169K ﹤0.01% 1956
2022
Q2
$304K Sell
481,100
-349,400
-42% -$268K ﹤0.01% 2118
2022
Q1
$947K Sell
830,500
-223,000
-21% -$266K ﹤0.01% 1666
2021
Q4
$2.37M Sell
1,053,500
-639,700
-38% -$1.61M 0.01% 1107
2021
Q3
$5.79M Buy
1,693,200
+527,800
+45% +$1.63M 0.02% 717
2021
Q2
$3.48M Buy
1,165,400
+390,800
+50% +$1.24M 0.01% 1033
2021
Q1
$2.5M Buy
774,600
+553,200
+250% +$1.85M 0.01% 1161
2020
Q4
$469K Buy
+221,400
New +$365K ﹤0.01% 1887
2017
Q1
Sell
-52,763
Closed -$71K 2502
2016
Q4
$71K Sell
52,763
-2,700
-5% -$3.53K ﹤0.01% 2287
2016
Q3
$87K Sell
55,463
-41,100
-43% -$63.1K ﹤0.01% 2144
2016
Q2
$128K Buy
+96,563
New +$452K ﹤0.01% 1943
2015
Q1
Sell
-37,663
Closed -$636K 2475
2014
Q4
$636K Buy
+37,663
New +$548K ﹤0.01% 1450

Other funds holding INFI

Two Sigma Advisers's INFI Position: Q3 2023 in Review

Two Sigma Advisers sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 58,900 shares — an estimated $12.4K sold.

Two Sigma Advisers first reported a position in INFI in Q4 2014 and held it in 15 quarters. The position peaked at $5.79M in Q3 2021. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

  • Two Sigma Advisers reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 58,900 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $12.4K.
  • Two Sigma Advisers first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 15 quarters.
  • Two Sigma Advisers's Infinity Pharmaceuticals, Inc. position peaked at $5.79M in Q3 2021.
  • 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.